BiotechTube

Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapy

Phase 3UNKNOWN
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Conditions

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Trial Timeline

Jul 13, 2020 → Jun 30, 2025

NCT ID
NCT04296370

About Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapy

Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapy is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation. The current trial status is unknown. This product is registered under clinical trial identifier NCT04296370. Target conditions include Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04296370Phase 3UNKNOWN

Competing Products

20 competing products in Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

See all competitors
ProductCompanyStageHype Score
Olanzapine and Fluoxetine combination (OFC) + FluoxetineEli LillyPhase 3
77
Olanzapine + Fluoxetine + PlaceboEli LillyPhase 3
77
Hetrombopag Olamine + PlaceboJiangsu Hengrui MedicinePhase 3
77
HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
77
Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
77
Irinotecan liposome、5-Fluorouracil、Leucovorin + Placebo、5-Fluorouracil、LeucovorinJiangsu Hengrui MedicinePhase 3
77
Dalpicilib + Abiraterone Acetate (II) + Androgen Deprivation Therapy + PrednisoneJiangsu Hengrui MedicinePhase 2
52
SHR8058 eye drops + saline eye drops.Jiangsu Hengrui MedicinePhase 3
77
Risankizumab + ComparatorAbbViePre-clinical
23
Chemotherapy + Cross-over to OsimertinibAstraZenecaPhase 3
77
AZD6765 + Placebo to AZD6765AstraZenecaPhase 2
52
TC-5214 + PlaceboAstraZenecaPhase 1
33
ACS patients treated with OAPAstraZenecaPre-clinical
23
AZD6738AstraZenecaPhase 1
33
MK-1942 + PlaceboMerckPhase 2
52
5-FU + Folinic Acid + Irinotecan + Cetuximab + AvelumabMerckPhase 2
52
simvastatin/ezetimibe + atorvastatin 20mgMerckApproved
85
BKM120NovartisPhase 2
52
LEE011NovartisPhase 2
52
AFQ056 + PlaceboNovartisPhase 2
52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85